leflunomide has been researched along with Extramembranous Glomerulopathy in 5 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Idiopathic membranous nephropathy (IMN) is the most common pathological type for nephrotic syndrome in adults in western countries and China." | 2.48 | Immunosuppressive treatment for nephrotic idiopathic membranous nephropathy: a meta-analysis based on Chinese adults. ( Chen, D; Hu, X; Li, L; Ma, Y; Mao, Z; Mei, C; Sun, L; Xie, G; Xu, C; Xu, J; Yang, L; Ye, C; Zhao, X, 2012) |
| "Diabetic kidney disease (DKD) combined with Membranous Nephropathy (MN) was observed in some patients with the increasing of Diabetic patients." | 1.72 | Retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy. ( Cui, S; Li, P; Li, Q; Li, W; Shang, S; Wang, C; Wang, W, 2022) |
| "Gender, age, and hypertension are associated with KD recurrence." | 1.43 | Clinicopathological features and prognosis of Kimura's disease with renal involvement in Chinese patients. ( Chen, Y; Liu, Z; Wang, J; Xu, F; Zeng, C, 2016) |
| " No serious adverse events were observed." | 1.39 | Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety. ( Lu, W; Xie, L; Xue, W; Yang, S; Yin, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shang, S | 1 |
| Cui, S | 1 |
| Wang, W | 1 |
| Wang, C | 1 |
| Li, P | 1 |
| Li, W | 1 |
| Li, Q | 1 |
| Guo, Y | 1 |
| Wu, X | 1 |
| Liu, L | 1 |
| Zhang, H | 1 |
| Yang, L | 2 |
| Chen, W | 1 |
| Yang, S | 1 |
| Xie, L | 1 |
| Xue, W | 1 |
| Yin, A | 1 |
| Lu, W | 1 |
| Chen, Y | 1 |
| Wang, J | 1 |
| Xu, F | 1 |
| Zeng, C | 1 |
| Liu, Z | 1 |
| Xie, G | 1 |
| Xu, J | 1 |
| Ye, C | 1 |
| Chen, D | 1 |
| Xu, C | 1 |
| Ma, Y | 1 |
| Hu, X | 1 |
| Li, L | 1 |
| Sun, L | 1 |
| Zhao, X | 1 |
| Mao, Z | 1 |
| Mei, C | 1 |
1 review available for leflunomide and Extramembranous Glomerulopathy
| Article | Year |
|---|---|
Immunosuppressive treatment for nephrotic idiopathic membranous nephropathy: a meta-analysis based on Chinese adults.
Topics: Adult; Alkylating Agents; Calcineurin Inhibitors; China; Chlorambucil; Clinical Trials as Topic; Cyc | 2012 |
1 trial available for leflunomide and Extramembranous Glomerulopathy
| Article | Year |
|---|---|
Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.
Topics: Adult; Autoantibodies; Biomarkers; Cyclophosphamide; Drug Therapy, Combination; Female; Glomerulonep | 2020 |
3 other studies available for leflunomide and Extramembranous Glomerulopathy
| Article | Year |
|---|---|
Retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy.
Topics: Creatinine; Diabetic Nephropathies; Drug Therapy, Combination; Glomerulonephritis, Membranous; Glyca | 2022 |
Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety.
Topics: Administration, Oral; Adolescent; Adult; Aged; Biopsy; China; Drug Therapy, Combination; Female; Glo | 2013 |
Clinicopathological features and prognosis of Kimura's disease with renal involvement in Chinese patients.
Topics: Adolescent; Adult; Angiolymphoid Hyperplasia with Eosinophilia; Anti-Inflammatory Agents; China; Fem | 2016 |